{
    "nctId": "NCT02104830",
    "briefTitle": "Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients",
    "officialTitle": "Multicenter Randomized Double-blind Phase III Clinical Study Comparing the Efficacy and Safety of a Single Dose Extimia\u00ae Versus Daily Filgrastim for Neutropenia Prophylaxis in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy",
    "overallStatus": "COMPLETED",
    "conditions": "Chemotherapy-induced Neutropenia",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 135,
    "primaryOutcomeMeasure": "Duration of Neutropenia CTCAE Grade 4",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Signed informed consent form;\n* Histologically verified diagnosis of stage IIb/III/IV breast cancer;\n* Age of 18-70 years inclusive;\n* Life expectancy of at least 6 months after inclusion in the study;\n* If the patient had received the chemotherapy for breast cancer, it should be finished 30 days before the beginning of the study;\n* ECOG Performance Status of 0- 2, not increasing within during 2 weeks before randomization;\n* ANC level of 1500/\u03bcL and more at the beginning of the study\n* Platelet count of 100 000/\u03bcL and more at the beginning of the study\n* Hemoglobin level of 90 g/l and more\n* Creatinine level \\<1.5 mg/dl\n* Total bilirubin level \\<1.5 \u00d7 the upper limit of normal (ULN)\n* ALT and/or AST levels \\<2.5\u00d7ULN (5\u00d7ULN for patients with liver metastases);\n* Alkaline phosphatase \\<5\u00d7ULN;\n* Left ventricular ejection fraction \\>50% and more;\n* If the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose of anthracyclines should not exceed 250 mg/m2 for doxorubicin or 540 mg/m2 for epirubicin,if in this study planned 6 cycles of chemotherapy ;\n* If the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose of anthracyclines should not exceed 350 mg/m2 for doxorubicin or 660 mg/m2 for epirubicin,if in this study planned 4 cycles of chemotherapy ;\n* Ability of the participant to follow the protocol requirements, according to the Investigator's opinion;\n* Patients of childbearing potential must implement reliable contraceptive measures during the study treatment, starting 4 weeks prior randomization and for 6 months after the last administration of the study drug;\n* Patients should be able to follow the Protocol procedures (according to Investigator's assessment.\n\nExclusion Criteria:\n\n* Patient has received two or more chemotherapy regimens for the metastatic breast cancer;\n* Documented hypersensitivity to filgrastim, pegfilgrastim, docetaxel, doxorubicin, dexamethasone and/or its excipients, PEGylated drugs, recombinant proteins.\n* Pregnancy or breastfeeding;\n* Systemic antibiotic therapy within 72 h prior empegfilgrastim/filgrastim administration;\n* Concomitant radiotherapy (except selective radiotherapy of bone metastases);\n* Surgery, radiotherapy (except selective radiotherapy of bone metastases), administration of any experimental drugs within 30 days prior randomization;\n* History of bone marrow/stem cell transplantation;\n* Conditions limiting the patient's ability to follow the protocol;\n* CTCAE grade 3-4 neuropathy;\n* HIV, HCV, HBV, T.Pallidum infection(s);\n* Acute or active chronic infections;\n* Severe concurrent diseases (for example, severe arterial hypertension, severe heart failure, and other);\n* Severe depression, schizophrenia, any other mental disorders;\n* Obstacles in intravenous administration of study drugs;\n* Simultaneous participation in other clinical trials, previous participation in other clinical trials within 30 days before entering into the trial, previous participation in the same trial.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}